Abstract
BackgroundIL-2 and IL-12 synergistically trigger the stimulation and proliferation of T and NK cells to mediate anti-tumor immunity. Although aldesleukin, a high-dose IL-2 intravenous (IV) infusion regimen, has been approved...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
